AGONIST OF V2 VASOPRESSIN RECEPTOR REDUCES DEPRESSIVE DISORDERS IN POST-STROKE PATIENTS

Cover Page


Cite item

Full Text

Abstract

Poststroke depression is one of the common psychiatric complications after stroke. Thus, the research of new ways for treatment depressed mood after stroke is actual. The previous researches revealed vasopressin to be effective in patients with memory, speech and motor function disorders after stroke. The purpose of the study was to investigate influence of vasopressin on depression after stroke. Fourteen patients with affective disorders have been treated with subendocrine doses of 1-desamino-8-D-arginin-vasopressin (DDAVP) daily by intranasal application during 1,5–2 months. Vasopressin was effective in correcting both apatoadinamic and anxious depression. Treatment effect was durable, lasts for 0,5–1 year after the first course of therapy. The results of this pilot study demonstrate perspective of using selective agonist of vasopressin V2 receptors, DDAVP, in therapy of post-stroke depression.

 

About the authors

S. G. Belokoskova

Institute of Experimental Medicine NWB RAMS

Author for correspondence.
Email: sgb@nm.ru
кандидат медицинских наук, научный сотрудник лаборатории психофизиологии эмоций физиологического отдела им. И.П. Павлова ФГБУ «Научно-исследовательский институт эксперимен- тальной медицины» Северо-Западного отделения РАМН Адрес: 197376, Санкт-Петербург, ул. Акад. Павлова, д. 12 Тел.: (812) 234-27-35 Россия

I. I. Stepanov

Institute of Experimental Medicine NWB RAMS

Email: igorstep@isl2044.spb.edu
доктор медицинских наук, ведущий научный сотрудник лаборатории химии и фармако- логии лекарственных средств отдела нейрофармакологии ФГБУ «Научно-исследовательский институт эксперимен- тальной медицины» Северо-Западного отделения РАМН Адрес: 197376, Санкт-Петербург, ул. Акад. Павлова, д. 12 Тел.: (812) 234-54-47 Россия

S. G. Tsikunov

Institute of Experimental Medicine NWB RAMS

Email: secikunov@yandex.ru
доктор медицинских наук, профессор, заведующий лабораторией психофизиологии эмоций физиологического отдела им. И.П. Павлова ФГБУ «Научно-исследовательский институт эксперимен- тальной медицины» Северо-Западного отделения РАМН Адрес: 197376, Санкт-Петербург, ул. Акад. Павлова, д. 12 Тел.: (812) 234-27-35 Россия

References

  1. Tsikunov S.G., Belokoskova S.G. Psychophysiological analisis of the influence of vasopressin on speech in patients with post-stroke aphasias. Spanish J. Psychology. 2007; 1 (1): 180–190.
  2. Tribollet E., Raufaste D., Maffrand J., Serradeil-Le Gal C. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study. Neuroendocrinology. 1999; 69 (2): 113–120.
  3. Vaccari C., Lolait S.J., Ostrowski N.L. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology. 1998; 139 (12): 5015–5033.
  4. Kato Y., Igarashi N., Hirasawa A. et al. Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation. 1995; 59 (3): 163–169.
  5. Liebsch G., Wotjak C.T., Landgraf R., Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci. Lett. 1996; 217 (2–3): 101–104.
  6. Griebel G., Simiand J., Serradeil-Le Gal C. et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc. Natl. Acad. Sci. USA. 2002; 99 (9): 6370–6375.
  7. Inder W.J., Donald R.A., Prickett T.C. et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol. Psychiatry. 1997; 42 (8): 744–747.
  8. Aguilera G., Subburaju S., Young S., Chen J. The parvocellular vasopressinergic system and responsiveness of the hypothalamic pituitary adrenal axis during chronic stress. Prog. Brain Res. 2008; 170: 29–39.
  9. Belova A.N. Shkaly, testy i oprosniki v nevrologii i nejrohirurgii. Ruk. dlya vrachej i naun. rabotnikov. M.: Samarskij dom pechati. 2004. 434 s.
  10. Leech N.L., Barrett K.C., Morgan G.A. SPSS for intermediate statistics: use and interpretation. 3rd ed. New-York: Psychology Press. 2008.
  11. Conover W. J. Practical nonparametric statistics. New-York: Wiley. 1980.
  12. Bortz J., Lienert G., Boehnke K. Verteilungsfreie Methoden in der Biostatistik. Berlin: Springer. 2000.
  13. Di Michele S., Ericson M., Sillen U. et al. The role of catecholamines in desmopressin induced locomotor stimulation. J. Neural. Transm. 1998; 105 (10–12): 1103–1115.
  14. Zhou A.W., Li W.X., Guo J., Du Y.C. Facilitation of AVP(4-8) on gene expression of BDNF and NGF in rat brain. Peptides. 1997; 18 (8): 1179–1187.
  15. Chen Q., Patel R., Sales A. et al. Vasopressin-induced neurotrophism in cultured neurons of the cerebral cortex: dependency on calcium signaling and protein kinase C activity. Neuroscience. 2000; 101: 19–26.
  16. Vartanyan G.A, Klement’ev B.I., Neujmina M.V., Novikova T.A. Nejrogumoral’naya indukciya strukturnoj i funkcional’noj kompensatornoj reorganizacii povrezhdennogo mozga. Vestnik RAMN. 1994; 1: 25–27.
  17. Belokoskova S.G., Cikunov S.G. Sravnitel’noe issledovanie vliyaniya arginin-vazopressina i piracetama na cerebral’nuyu gemodinamiku u bol’nyh, perenesshih insul’t. Regionarnoe krovoobraschenie i mikrocirkulyaciya. 2005; 4: 20–26.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 "Paediatrician" Publishers LLC



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies